➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Medtronic
Boehringer Ingelheim
Merck
Dow

Last Updated: June 14, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Anlotinib


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Anlotinib?

Anlotinib is an investigational drug.

There have been 207 clinical trials for Anlotinib. The most recent clinical trial was a Phase 2 trial, which was initiated on November 30th 2018.

The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Carcinoma. The leading clinical trial sponsors are Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd, and Sun Yat-sen University.

There are ten US patents protecting this investigational drug and seventy-two international patents.

Recent Clinical Trials for Anlotinib
TitleSponsorPhase
Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 2
Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)Tianjin Medical University Cancer Institute and HospitalPhase 2
Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLCAllist Pharmaceuticals, Inc.Phase 2

See all Anlotinib clinical trials

Clinical Trial Summary for Anlotinib

Top disease conditions for Anlotinib
Top clinical trial sponsors for Anlotinib

See all Anlotinib clinical trials

US Patents for Anlotinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Anlotinib   Get Started Free Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)meth- yl)cyclopropanamine, its crystalline form and its salts Advenchen Pharmaceuticals, LLC (Moorpark, CA)   Get Started Free
Anlotinib   Get Started Free Methods and uses of quinoline derivatives in the treatment of soft tissue sarcomas and pharmaceutical compositions for treatment of same   Get Started Free
Anlotinib   Get Started Free Method for treating tumour, pharmaceutical composition and medicinal kit   Get Started Free
Anlotinib   Get Started Free Quinoline derivative against non-small cell lung cancer   Get Started Free
Anlotinib   Get Started Free Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)meth- yl)cyclopropanamine, its crystalline form and its salts Advenchen Pharmaceuticals, LLC (Moorpark, CA)   Get Started Free
Anlotinib   Get Started Free Use of quinoline derivatives for treating oesophageal cancer and treatment method, pharmaceutical composition and kit thereof Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Lianyungang, CN)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Anlotinib

Drugname Country Document Number Estimated Expiration Related US Patent
Anlotinib Australia AU2016257816 2035-05-04   Get Started Free
Anlotinib Brazil BR112017023639 2035-05-04   Get Started Free
Anlotinib Canada CA2984444 2035-05-04   Get Started Free
Anlotinib China CN107771078 2035-05-04   Get Started Free
Anlotinib China CN110172057 2035-05-04   Get Started Free
Anlotinib China CN110292579 2035-05-04   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Medtronic
McKinsey
Dow
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.